Sign Up to like & get
recommendations!
2
Published in 2023 at "Annals of Medicine"
DOI: 10.1080/07853890.2022.2164611
Abstract: Abstract Background There is a lack of evidence regarding whether combination therapy of hypomethylating agents (HMAs) has better outcomes than HMA monotherapy in patients with Philadelphia chromosome-negative accelerated or blast phase myeloproliferative neoplasms (MPN-AP/BP). Materials…
read more here.
Keywords:
hypomethylating agents;
combination;
hmas plus;
accelerated blast ... See more keywords